Am I correct in assuming you are wondering how your one cycle of Bendamustine + Rituximab (BR) might influence the effectiveness of your next treatment? People treated with older drugs like Bendamustine have been shown to have a higher incidence of del 17p and mutated TP53 chromosomal damage in their CLL. (The TP53 gene is located on chromosome 17, so is usually lost with 17p del CLL.) If that genetic damage becomes present, it means re-treatment with Bendamustine or older drugs reliant on functional TP53 is much less effective.
You only had one cycle of BR, so are less likely to have 17p del or mutated TP53. Your oncologist has also probably done FISH testing to check if you have 17p del, so ask! Targeted therapies, such as venetoclax, rely on other means than having a functional TP53 gene to kill CLL cells, so your treatment with venetoclax should work well. Venetoclax is commonly paired with obinutuzumab, a second generation and more effective version of rituximab, or a Bruton's Tyrosine Kinase inhibitor, such as acalabrutinib, ibrutinib or zanubrutinib, all of which aren't reliant on having a functional TP53.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.